Cargando…

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations

INTRODUCTION: Allelic frequency distribution of drug metabolizing enzyme genes among populations is important to identify risk groups for adverse drug reaction and to select representative populations for clinical trials. Although India emerged as an important hub for clinical trials, information ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Nizamuddin, Sheikh, Dubey, Shivendra, Singh, Sakshi, Sharma, Saurav, Machha, Pratheusa, Thangaraj, Kumarasamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850565/
https://www.ncbi.nlm.nih.gov/pubmed/33536773
http://dx.doi.org/10.2147/PGPM.S272015
_version_ 1783645465364922368
author Nizamuddin, Sheikh
Dubey, Shivendra
Singh, Sakshi
Sharma, Saurav
Machha, Pratheusa
Thangaraj, Kumarasamy
author_facet Nizamuddin, Sheikh
Dubey, Shivendra
Singh, Sakshi
Sharma, Saurav
Machha, Pratheusa
Thangaraj, Kumarasamy
author_sort Nizamuddin, Sheikh
collection PubMed
description INTRODUCTION: Allelic frequency distribution of drug metabolizing enzyme genes among populations is important to identify risk groups for adverse drug reaction and to select representative populations for clinical trials. Although India emerged as an important hub for clinical trials, information about the pharmacogenetic diversity for this region is still lacking. Here, we investigated genetic diversity of cytochrome-P450-2C9 (CYP2C9) gene which metabolizes wide range of drugs and is highly expressed in the human liver. METHODS: In total, 1278 individuals from 36 diverse Indian populations, 210 individuals from in-house data-repository and 489 other South Asian samples from the 1000 Genomes Project were selected. Variants observed in CYP2C9 gene were subjected to various statistical analyses. RESULTS: High frequency of CYP2C9*3 (~13%) and CYP2C9*3/*3 (~1%) was observed among South Asians, compared to 21 populations living outside the Indian subcontinent. The allelic/genotypic frequency does not correlate with geographical location or linguistic affiliation, except populations speaking Tibeto-Burmans language, who have lower frequency of CYP2C9*3 and CYP2C9*3/*3. Since, South Asians practice strict endogamy, presence of unique mutation and high frequency of homozygous genotypes not surprising. CYP2C9*3 has been associated with therapeutic response.The effect of CYP2C9*3/*3 is more pronounced compared to heterozygous and wild type homozygous genotypes as evident in many in vitro studies. As South Asians have high frequency, it would be interesting to explore potential of CYP2C9*3 as a marker for personalized therapy. Our study revealed several rare functional variants, which form eight novel and rare haplotypes of CYP2C9 (CYP2C9*63–*70). Of which, CYP2C9*64, *65, *66, *68, *69 and *70 haplotypes are South Asian-specific. CONCLUSION: Overall, we find high genetic heterogeneity within South Asians and identified South Asian-specific putative functional CYP2C9 haplotypes. High frequency of CYP2C9*3 and CYP2C9*3/*3 was observed in South Asian populations. Taken together, current study greatly enriches the knowledge of naturally occurring CYP2C9 variants and its diversity in South Asia, which are relevant to further CYP2C9-related functional research and for personalized medicine.
format Online
Article
Text
id pubmed-7850565
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78505652021-02-02 CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations Nizamuddin, Sheikh Dubey, Shivendra Singh, Sakshi Sharma, Saurav Machha, Pratheusa Thangaraj, Kumarasamy Pharmgenomics Pers Med Original Research INTRODUCTION: Allelic frequency distribution of drug metabolizing enzyme genes among populations is important to identify risk groups for adverse drug reaction and to select representative populations for clinical trials. Although India emerged as an important hub for clinical trials, information about the pharmacogenetic diversity for this region is still lacking. Here, we investigated genetic diversity of cytochrome-P450-2C9 (CYP2C9) gene which metabolizes wide range of drugs and is highly expressed in the human liver. METHODS: In total, 1278 individuals from 36 diverse Indian populations, 210 individuals from in-house data-repository and 489 other South Asian samples from the 1000 Genomes Project were selected. Variants observed in CYP2C9 gene were subjected to various statistical analyses. RESULTS: High frequency of CYP2C9*3 (~13%) and CYP2C9*3/*3 (~1%) was observed among South Asians, compared to 21 populations living outside the Indian subcontinent. The allelic/genotypic frequency does not correlate with geographical location or linguistic affiliation, except populations speaking Tibeto-Burmans language, who have lower frequency of CYP2C9*3 and CYP2C9*3/*3. Since, South Asians practice strict endogamy, presence of unique mutation and high frequency of homozygous genotypes not surprising. CYP2C9*3 has been associated with therapeutic response.The effect of CYP2C9*3/*3 is more pronounced compared to heterozygous and wild type homozygous genotypes as evident in many in vitro studies. As South Asians have high frequency, it would be interesting to explore potential of CYP2C9*3 as a marker for personalized therapy. Our study revealed several rare functional variants, which form eight novel and rare haplotypes of CYP2C9 (CYP2C9*63–*70). Of which, CYP2C9*64, *65, *66, *68, *69 and *70 haplotypes are South Asian-specific. CONCLUSION: Overall, we find high genetic heterogeneity within South Asians and identified South Asian-specific putative functional CYP2C9 haplotypes. High frequency of CYP2C9*3 and CYP2C9*3/*3 was observed in South Asian populations. Taken together, current study greatly enriches the knowledge of naturally occurring CYP2C9 variants and its diversity in South Asia, which are relevant to further CYP2C9-related functional research and for personalized medicine. Dove 2021-01-27 /pmc/articles/PMC7850565/ /pubmed/33536773 http://dx.doi.org/10.2147/PGPM.S272015 Text en © 2021 Nizamuddin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Nizamuddin, Sheikh
Dubey, Shivendra
Singh, Sakshi
Sharma, Saurav
Machha, Pratheusa
Thangaraj, Kumarasamy
CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
title CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
title_full CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
title_fullStr CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
title_full_unstemmed CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
title_short CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
title_sort cyp2c9 variations and their pharmacogenetic implications among diverse south asian populations
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850565/
https://www.ncbi.nlm.nih.gov/pubmed/33536773
http://dx.doi.org/10.2147/PGPM.S272015
work_keys_str_mv AT nizamuddinsheikh cyp2c9variationsandtheirpharmacogeneticimplicationsamongdiversesouthasianpopulations
AT dubeyshivendra cyp2c9variationsandtheirpharmacogeneticimplicationsamongdiversesouthasianpopulations
AT singhsakshi cyp2c9variationsandtheirpharmacogeneticimplicationsamongdiversesouthasianpopulations
AT sharmasaurav cyp2c9variationsandtheirpharmacogeneticimplicationsamongdiversesouthasianpopulations
AT machhapratheusa cyp2c9variationsandtheirpharmacogeneticimplicationsamongdiversesouthasianpopulations
AT thangarajkumarasamy cyp2c9variationsandtheirpharmacogeneticimplicationsamongdiversesouthasianpopulations